



PRESS RELEASE

06 September 2024 08:30:00 CEST

AcouSort enters into collaboration with University College Dublin

AcouSort has entered into a formal collaboration with Dr Alfonso Blanco, Director of Flow Cytometry at Conway Institute, University College Dublin (UCD). Studying Extracellular Vesicles (EVs) with flow cytometry is increasingly popular and there is a massive interest in using the technique to further deepen the understanding of these intriguing nanoparticles. The collaboration involves the placement of an AcouTrap system in the UCD lab during the collaboration period

Dr Blanco is a prominent Key Opinion Leader (KOL) in the flow cytometry field, especially within the field of characterization of EVs using flow cytometry. The lab at the Conway Institute is very well equipped with a number of high-end flow cytometers.

AcouSort has previously visited Dr. Blanco's laboratory demonstrating our AcouTrap system, and during this new collaboration, an AcouTrap system is placed at the facilities in Dublin to be used for EV sample preparation prior to flow cytometry analysis. The collaboration with the group at Conway Institute is an important step for AcouSort developing applications and generate new knowledge and independent data showing the benefits of using acoustic trapping as a tool for flow cytometry sample preparation.

"Collaborations with academia is a very important way to explore and establish new technology within the EV field and to gain further recognition of the benefits of using acoustic technology for simplifying and automating sample preparation," says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).